Harlan Laboratories Contract Research Services (CRS) is investing $4.5 million in its Itingen, Switzerland site. The investment will expand its range of testing and research services at the site and will include enhancements to the inhalation facility, upgrading the barrier protected area for chronic and subchronic studies and an entire floor dedicated to reproductive and rodent toxicology. The company will also build new lab areas for clinical diagnostics, biochemical analysis and fetal pathology.
The investment follows Harlan's consolidation of its Füllinsdorf operations into the Itingen site. Harlan has also launched a recruitment effort to expand its Histology expertise, along with new processing equipment.
“This is an exciting development which we believe will offer many benefits to our customers,” said Hans Thunem, chief executive officer of Harlan Laboratories. “We indicated last year that our commitment to our operations in Switzerland was strong but being tested by lack of profitability. With the results delivered by our employees over the last 12 months, it is rewarding to now be able to make new investments in our Swiss operations.”